|
SB2462
Status and Testimony
|
RELATING TO CONTROLLED SUBSTANCES.
Requires, by September 1, 2020, that the department of health request the
Drug Enforcement Administration to grant a federal schedule I exemption for
the medical use of cannabis in Hawaii.
|
CPH, JDC
|
|
SB2226
Status and Testimony
|
RELATING TO PHARMACY BENEFIT MANAGERS.
Establishes business practice and transparency reporting requirements for
pharmacy benefit managers. Replaces the registration requirement for
pharmacy benefit managers with a licensing requirement. Increases penalties
for violations of the pharmacy benefit managers law. Effective 1/1/2021.
|
CPH, JDC
|
|
SB2280
Status and Testimony
|
RELATING TO PHARMACY BENEFIT MANAGERS.
Prohibits pharmacy benefit managers from engaging in self-serving business
practices. Replaces registration requirement with license requirement for
pharmacy benefit managers. Increases pharmacy benefit manager reporting
requirements to the insurance commissioner. Increases application and
renewal fees and penalties for failure to renew a license.
|
CPH, JDC
|
|
SB2276
Status and Testimony
|
RELATING TO PRESCRIPTION DRUGS.
Requires drug manufacturers to notify prescription drug benefit plans and
pharmacy benefit managers if a proposed increase in the wholesale price of
certain drugs would result in a sixteen per cent or more price increase over
a two year period. Requires the drug manufacturer to identify and report to
the insurance commissioner information on certain drugs whose wholesale
acquisition cost increases by a certain amount during a specified time
frame. Imposes fines.
|
CPH, JDC
|
|
SB2582
Status and Testimony
|
RELATING TO HEALTH.
Authorizes advanced practice registered nurses, in addition to physicians, to
practice medical aid in dying in accordance with their scope of practice and
prescribing authority. Reduces the mandatory waiting period between oral
requests from twenty days to fifteen days. Waives the mandatory waiting
period for those terminally ill individuals not expected to survive the
mandatory waiting period.
|
CPH, JDC
|
|
SB2278
Status and Testimony
|
RELATING TO HEALTH INSURANCE.
Establishes disclosure and consent requirements for nonparticipating health
care providers. Prohibits nonparticipating health care providers from
balance billing patients in specific circumstances. Establishes rate
calculation requirements for reimbursement of nonparticipating providers.
|
CPH, JDC
|
|
SB2539
Status and Testimony
|
RELATING TO HEALTH CARE.
Requires health insurers, mutual benefit societies, and health maintenance
organizations to provide coverage for a comprehensive category of
reproductive health services, drugs, devices, products, and procedures.
Prohibits discrimination in the provision of reproductive health care
services. Effective 3/15/2021.
|
CPH, JDC
|